Azzad Asset Management Inc. ADV Purchases 1,969 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Azzad Asset Management Inc. ADV increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 74.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,620 shares of the biopharmaceutical company’s stock after buying an additional 1,969 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Alnylam Pharmaceuticals were worth $2,107,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after purchasing an additional 240,534 shares in the last quarter. Geode Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after buying an additional 75,936 shares during the period. Orbis Allan Gray Ltd grew its stake in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares during the last quarter. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $662,837,000. Finally, American Century Companies Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock valued at $584,957,000 after acquiring an additional 33,411 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,780 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares in the company, valued at $20,852,324.55. This trade represents a 4.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the transaction, the executive vice president directly owned 29,728 shares of the company’s stock, valued at approximately $10,787,399.36. This trade represents a 4.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 56,955 shares of company stock worth $24,072,733. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Trading Down 0.9%

NASDAQ ALNY opened at $328.16 on Monday. The firm has a market capitalization of $43.35 billion, a PE ratio of 1,367.33 and a beta of 0.35. The stock’s 50 day moving average is $389.54 and its 200 day moving average is $425.73. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ALNY shares. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a report on Monday, January 12th. Finally, Royal Bank Of Canada dropped their price target on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $477.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.